Bronchiolitis obliterans (BO) is one of the most devastating complications after allogeneic stem cell transplantation (HSCT). However, its true pathogenesis is still to be elucidated. We conducted this study to find whether tissue damage due to high-dose chemo-radiotherapy is related to its pathogenesis. In all, 144 patients who received allogeneic HSCT between May 1999 and October 2001, and survived more than 80 days after transplant, were analyzed. Clinical course, pulmonary function tests, imaging studies including CT scan, and pathology results were reviewed. The overall incidence of BO was 9.7% (14/ 144). The cumulative incidence of BO at 2 years after transplant was 17% with myeloablative conditioning, and 2.3% with reduced intensity conditioning (P ¼ 0.024). Multivariate analysis showed that myeloablative conditioning was the only factor which affected the incidence of BO. Development of BO did not significantly affect the overall survival of patients. However, if they developed BO earlier than 200 days post transplant, the prognosis was significantly worse than if they developed it later than 200 days post transplant (P ¼ 0.003) or if they did not develop BO (P ¼ 0.002). Our results imply that tissue damage secondary to intensive chemo-radiotherapy may contribute to the pathogenesis of BO.
sity; allogeneic stem cell transplantation Allogeneic hematopoietic stem cell transplantation (HSCT) is often associated with pulmonary complications. With the development of potent antibiotics and antifungal agents, the spectrum of pulmonary complications has shifted from infectious to noninfectious etiologies.
Bronchiolitis obliterans (BO) is a late-onset noninfectious pulmonary complication manifesting with clinical symptoms such as cough, dyspnea, and wheezing due to obstruction of small airways. The onset of BO varies from 80 days to as late as 9 years following HSCT. [1] [2] [3] [4] [5] [6] Pulmonary function tests and radiological findings are also indicative of airflow obstruction. Lung pathology shows bronchiolar inflammation with submucosal and peribronchiloar fibrosis resulting in concentric airway narrowing or obstruction. [6] [7] [8] [9] [10] The incidence of BO following allogeneic HSCT varies from 2 to 10% between studies 1, 3, 4, 6, 7, [11] [12] [13] partly because uniform diagnostic criteria are lacking. Unfortunately, effective treatment of BO has not been established. Most patients are resistant to immunosuppressive therapy. Mortality rates are high, and vary from 14 to 100%. [1] [2] [3] [4] 6, 7, 12 To date, chronic graft-versus-host disease (GVHD), methotrexate given long-term, and low-serum immunoglobulin levels have been identified as risk factors for BO. [1] [2] [3] [4] 12, 14 Chronic GVHD particularly has been reported to be closely associated with BO, and sometimes BO is recognized as a lung manifestation of chronic GVHD. However, there is some evidence to suggest that the etiology of BO is not only related to graft-versus-host reaction, but that it is multifactorial. There are two reported cases of fatal BO after autologous HSCT, 15 which show that tissue damage due to high-dose chemotherapy alone can cause BO. Many patients with BO have preceding pulmonary infection, implying that infection may also be involved in the development of BO. The fact that some cases progress rapidly to fatal pulmonary dysfunction while others are stable for years also implies that BO may not be a single disease entity.
Allogeneic HSCT with reduced-intensity conditioning regimens are currently being explored. Reduced-intensity conditioning decreases transplant-related mortality (TRM) and enables allogeneic HSCT to be used in patients over 50 years of age, and those who have been heavily pretreated, including with autologous HSCT, or to those with other medical problems. [16] [17] [18] [19] In addition, allogeneic HSCT with reduced-intensity conditioning is being explored for patients with solid tumors. 20 If lung tissue injury caused by conditioning chemoradiotherapy is involved in the pathogenesis of BO, the incidence of BO might be decreased after reduced-intensity conditioning. To test this hypothesis, we compared the incidence of BO following allogeneic HSCT with reducedintensity conditioning to that following myeloablative conditioning.
Patients and methods

Patients
Patients who underwent allogeneic HSCT at the National Cancer Center Hospital in Tokyo, Japan between May 1999 and October 2001 were analyzed. Patients older than 55 years of age with hematologic malignancies, or those with other medical problems, were transplanted with reduced-intensity conditioning regimens, whereas others were transplanted with myeloablative conditioning regimens. Patients with solid tumors were transplanted with reduced-intensity conditioning regimens regardless of age or comorbidities. The reduced-intensity conditioning regimens had been approved by the Institutional Review Board (IRB). The transplant procedures were explained to the patients and family members and written informed consent was obtained.
Conditioning regimens
Cyclophosphamide (CY, 60 mg/kg once daily i.v. for 2 days, total dose 120 mg/kg)/total body irradiation (TBI, 12 Gy divided into six fractions) or busulfan (BU, 4 mg/kg p.o. in divided doses for 4 days, total dose 16 mg/kg)/CY (60 mg/kg once daily i.v. for 2 days, total dose 120 mg/kg) were used as myeloablative conditioning. Fludarabine (Flu, 30 mg/m 2 once daily i.v. for 6 days, total dose 180 mg/m 2 )/ BU (4 mg/kg p.o. in divided doses for 2 days, total dose 8 mg/kg) 18 or cladribine (Cla, 0.11 mg/kg once daily i.v. for 6 days, total dose 0.66 mg/kg)/BU (4 mg/kg p.o. in divided doses for 2 days, total dose 8 mg/kg) 19 were used as reduced-intensity conditioning. Patients who underwent reduced-intensity transplantation from an HLA 1 antigenmismatched donor, or who had solid tumors, received antithymocyte globulin (ATG, Thymoglobulin, IMTIXSangstat, Lyon, France, 2.5 mg/kg once daily i.v. for 4 or 2 days, total dose 5 or 10 mg/kg, respectively). 21 
GVHD prophylaxis and treatment
Cyclosporin A was administered at a dose of 3 mg/kg/day by continuous intravenous infusion and the dose was adjusted to keep the steady-state level between 150 and 400 ng/ml. Methotrexate was also used at a dose of 10-15 mg/m 2 once daily i.v. on day 1, 7-10 mg/m 2 on days 3 and 6, and optionally on day 11. In all, 40 patients who received reduced-intensity conditioning followed by transplantation from an HLA-matched relative did not receive methotrexate.
Acute GVHD was diagnosed and graded according to established criteria. 22 Patients who developed grade II-IV GVHD were initially treated with methylprednisolone at 1-2 mg/kg/day. Pulsed steroid, ATG, and/or mycophenolate mofetil (MMF) were used for patients whose GVHD was refractory to standard-dose steroids.
Infection prophylaxis
Ciprofloxacin and fluconazole were given from the beginning of conditioning until engraftment or discontinuation of immunosuppression, whichever came later. Prophylaxis against herpes simplex infection was with acyclovir 1000 mg/day p.o. in divided doses (or 750 mg/day i.v. in divided doses) until day 35 post transplant, and then at a lower dose (200-400 mg/day) until the end of immunosuppressive therapy, as reported previously. 23 All patients received trimethoprim-sulfamethoxazole orally or inhaled pentamidine as prophylaxis against Pneumocystis carinii.
Diagnosis of BO
A diagnosis of BO was established if patients developed symptoms of dyspnea, wheezing, and cough which did not respond to up to 2 mg/kg/day of prednisone, in addition to, either more than a 50% decline in FEV 1 , a CT scan of the chest showing air trapping and mosaic pattern in the lung, or histology of biopsy/autopsy specimens of the lung indicating severe airflow obstruction. Patients with asthma or active infections were excluded according to responses to beta-agonists, physical examination, laboratory data, or chest X-ray/CT scan, respectively.
Statistical analysis
All statistical analyses were performed using the SPSS 11.0J software (SPSS Inc., Chicago, IL, USA). Probabilities of BO and survival were calculated according to the method of Kaplan and Meier and compared using the long-rank test. The univariate and multivariate Cox proportional hazard models were used to analyze the influence of selected variables on the risk of BO. Variables for multivariate models were selected with backwards stepwise elimination, with significance exceeding 0.1 as the criterion for removal from the models.
Results
Patient characteristics
Between May 1999 and October 2001, 163 patients underwent allogeneic HSCT at the National Cancer Center Hospital in Tokyo, Japan. Among them, 19 patients who died before 80 days post-transplant were excluded from the analysis. Patient characteristics are summarized in Table 1 . In all, 96 patients received myeloablative conditioning regimens: 53 patients received CY/TBI, 32 received BU/ CY, and 11 received other conditioning regimens, most of which were based on CY/TBI. Also, 48 patients received reduced-intensity conditioning regimens including seven with solid tumors: 34 patients received Flu/BU and 14 Cla/ BU. In total, 27 patients received ATG.
Clinical findings of BO
Fourteen patients met the diagnostic criteria for BO mentioned above (Table 2a) . The median time from transplantation to onset of symptoms was 221 days (102-350). All patients who were diagnosed with BO had cough and dyspnea, and all had wheezing. Results of pulmonary function tests both before transplantation and after the onset of symptoms were available for eight patients (Table 2b ). All of them showed a marked decline of FEV 1 . Chest X-ray and thin slice CT scans were reviewed for all, and 13 of 14 patients, respectively. Seven patients were found to have hyperinflation of the lungs evident on chest X-ray. Out of 13 patients, 12 were found to have airflow obstruction on thin slice CT scanning. CT findings included hyperinflation, wall thickening, and dilatation of bronchi or bronchioles, decreased attenuation of vascular markings, and mosaic attenuation evident on end-expiration. Only one patient was diagnosed with BO on autopsy. Open-lung biopsies were not performed because of performance status, immunosuppression, or lack of patient consent.
Seven of 14 patients died at a median of 191 days (44-618) after the onset of symptoms. In six cases, BO or BO complicated by infection was the cause of death in spite of immunosuppressive therapy such as corticosteroids, cyclosporine A or tacrolimus, and MMF. In one case, disease progression and infection were the causes of death.
Risk factors of BO
The cumulative incidence of BO at 2 years after transplantation was 17% with myeloablative conditioning and 2.3% with reduced intensity conditioning (P ¼ 0.024, Figure 1) . Patients who developed BO tended to have poorer survival than those who did not, although the difference was not significant (Figure 2a) . However, patients who developed BO before day 200 post-transplant had a significantly worse prognosis compared to those who developed BO after day 200 (Figure 2b , P ¼ 0.003). These had significantly worse survival compared to those who did not (P ¼ 0.002).
Univariate analysis showed that females, patients with chronic GVHD, or those who had received MTX had a tendency to develop BO (Table 3 ). Multivariate analysis confirmed reduced-intensity conditioning to be the only factor related to decreased incidence of BO. MTX use was excluded from the variables on multivariate analysis because it was not an independent factor, as patients who received myeloablative conditioning also received MTX. Chronic GVHD was also not identified as a risk factor in this analysis.
Discussion
In this study, BO was observed in 9.7% of all recipients (14 out of 144 cases) and in 15% of patients who received myeloablative conditioning. This is higher than previously reported, which is at least partly due to the lack of defined diagnostic criteria for BO. For lung transplant recipients, an expert group from the International Society for Heart and Lung Transplantation created clinically applicable systems for the staging of chronic rejection based on histology 24 and an objective clinical marker. 25 According to the latter, bronchiolitis obliterans syndrome (BOS) can be diagnosed without histology if the FEV 1 declines more than or equal to 20% from the post-transplant baseline, not explained by acute rejection, infection, or problems related to the bronchial anastomosis.
The diagnosis of BO requires histological features such as scar formation and fibrosis in small airways, often associated with intimal thickening and sclerosis of vessels. Transbrochial biopsy may not be reliable because of patchy distribution of the lesions. Open lung biopsy, on the other hand, may be associated with some morbidity and possibly mortality. Thus, in many cases these patients are only diagnosed as BOS. For recipients of allogeneic HSCT, it may be more difficult to obtain a histological diagnosis because HSCT recipients are generally more immunosuppressed than lung transplant recipients, and often neutropenic and/or thrombocytopenic at the time they need a diagnosis. Thus, it may be more practical to make the clinical diagnosis of BO (or make disease entity of BOS) based on clinical signs and symptoms, pulmonary function tests, and radiological findings.
Thin-section CT scans are particularly useful and the signs of air trapping are reported to be sensitive, specific, and accurate for diagnosing BOS following lung transplantation. 26, 27 In our study, most cases who had clinical symptoms and decline in FEV 1 also had abnormal findings on thin-section CT such as hyperinflation of the lung fields, wall thickening, and dilatation of bronchi or bronchioles, decreased attenuation of vascular markings due to hypoxic vasoconstriction, or mosaic attenuation evident on endexpiration.
For lung transplant recipients, BO is one of the most significant complications. Up to 70% of recipients develop BO and more than half die. This is recognized as chronic graft rejection and there are two working hypotheses on etiology. One is immunological rejection due to alloreactive lymphocytes and the other is that multiple factors such as prolonged ischemia, surgical manipulation, and aspiration cause injury to epithelium and progressive change.
BO occurs in settings other than allogeneic HSCT or lung transplantation. Although extremely rare, two cases of fatal BO have been reported in autologous HSCT recipients, which suggests that tissue damage by high-dose chemotherapy alone might cause BO. BO is also known to be associated with a number of connective tissue diseases, particularly rheumatoid arthritis, which also implies that immunological responses are involved in the pathogenesis. BO also develops after inhalational injury with toxins, infections with respiratory syncytial virus, parainfluenza virus, influenza virus, adenovirus, measles virus, and Mycoplasma pneumonia.
Considering all these cases, the pathogenesis of BO following allogeneic HSCT may be multi-factorial, involving tissue damage, GVH reaction, and infections.
In the current series, only one out of 48 (2.0%) patients who received reduced-intensity conditioning developed BO, while 14 out of 96 (15%) developed BO after myeloablative conditioning. The cumulative incidence of BO at 2 years after HSCT was 2.3% with reduced-intensity conditioning compared to 17% with myeloablative conditioning (P ¼ 0.024). Univariate and multivariate analysis of various variables such as sex, age, conditioning regimen, related or unrelated donor, PBSC or bone marrow as stem cell source, HLA mismatch, MTX use, acute GVHD, and chronic GVHD confirmed that reduced-intensity conditioning was associated with a lower incidence of BO. Any influence of MTX could not be excluded in this study. However, the doses of MTX used here were much less than those used when MTX was identified as a risk factor for BO. There was some imbalance between the myeloablative and reduced-intensity groups, but it was impossible to analyze this on multivariate analysis due to the small number of patients with each disease.
These results support our hypothesis that lung tissue damage caused by pre-transplant conditioning chemotherapy or irradiation is involved in the pathogenesis of BO. This probably explains why only a few cases of BO respond to immunosuppressive therapy. Cases of BO in which chronic GVHD is mainly involved in the pathogenesis may be more responsive to immunosuppressive therapy. There is a report which claims that the incidence of idiopathic pneumonia syndrome (IPS) is lower after nonmyeloablative transplantation. 28 As far as we know, the current study is the first to report a lower incidence of BO after reduced-intensity transplantation compared to that seen after myeloablative transplantation. In addition, the poor prognosis of the patients who develop BO before day 200 after transplantation confirmed the report from Minnesota group. 3 In conclusion, we showed that a lower incidence of BO is observed with reduced intensity, rather than myeloablative conditioning. A prospective study is required to ascertain which chemotherapeutic agents and irradiation doses are particularly harmful and play a role in the pathogenesis of BO. 
